Richard T Lee1, Andrea Barbo2, Gabriel Lopez2, Amal Melhem-Bertrandt2, Heather Lin2, Olufunmilayo I Olopade2, Farr A Curlin2. 1. Richard T. Lee, Andrea Barbo, Gabriel Lopez, Amal Melhem-Bertrandt, and Heather Lin, University of Texas MD Anderson Cancer Center, Houston, TX; Olufunmilayo I. Olopade, University of Chicago, Chicago, IL; and Farr A. Curlin, Duke University, Durham, NC. rtlee@mdanderson.org. 2. Richard T. Lee, Andrea Barbo, Gabriel Lopez, Amal Melhem-Bertrandt, and Heather Lin, University of Texas MD Anderson Cancer Center, Houston, TX; Olufunmilayo I. Olopade, University of Chicago, Chicago, IL; and Farr A. Curlin, Duke University, Durham, NC.
Abstract
PURPOSE: Patients with cancer commonly use complementary and alternative medicine, including herbs and supplements (HS), during cancer treatment. This national survey explored oncologists' knowledge, attitudes, and practice patterns regarding HS use by their patients. METHODS: A survey was sent by mail and e-mail to a random sample of 1,000 members of the American Society for Clinical Oncology. The questions covered several topics: communication patterns, attitudes about HS, education about HS, response to HS use among hypothetical patients with cancer, knowledge of HS adverse effects, and demographic information. RESULTS: Among eligible oncologists, 392 (42%) responded to the questionnaire. Most were white (75%) men (71%), with a mean age of 48 years (standard deviation, 9.8 years). On average, oncologists discussed use of HS with 41% of their patients; only 26% of discussions were initiated by the oncologist. Two of three oncologists indicated they did not have enough knowledge to answer questions from patients regarding HS, and 59% had not received any education about the topic. Physician factors associated with having initiated discussions with patients about the use of HS included female sex, higher self-reported knowledge, prior education about HS, increased knowledge about HS adverse effects and interactions, and estimating that > 40% of one's patients with cancer use HS. CONCLUSION: Fewer than one half of oncologists are initiating discussions with patients about HS use, and many indicate that lack of knowledge and education is a barrier to such discussions. Improving physician education about HS may facilitate more physician-patient communication about this important topic.
PURPOSE:Patients with cancer commonly use complementary and alternative medicine, including herbs and supplements (HS), during cancer treatment. This national survey explored oncologists' knowledge, attitudes, and practice patterns regarding HS use by their patients. METHODS: A survey was sent by mail and e-mail to a random sample of 1,000 members of the American Society for Clinical Oncology. The questions covered several topics: communication patterns, attitudes about HS, education about HS, response to HS use among hypothetical patients with cancer, knowledge of HS adverse effects, and demographic information. RESULTS: Among eligible oncologists, 392 (42%) responded to the questionnaire. Most were white (75%) men (71%), with a mean age of 48 years (standard deviation, 9.8 years). On average, oncologists discussed use of HS with 41% of their patients; only 26% of discussions were initiated by the oncologist. Two of three oncologists indicated they did not have enough knowledge to answer questions from patients regarding HS, and 59% had not received any education about the topic. Physician factors associated with having initiated discussions with patients about the use of HS included female sex, higher self-reported knowledge, prior education about HS, increased knowledge about HS adverse effects and interactions, and estimating that > 40% of one's patients with cancer use HS. CONCLUSION: Fewer than one half of oncologists are initiating discussions with patients about HS use, and many indicate that lack of knowledge and education is a barrier to such discussions. Improving physician education about HS may facilitate more physician-patient communication about this important topic.
Authors: Felicity L Bishop; Philip Prescott; Yean Koon Chan; Jemma Saville; Erik von Elm; George T Lewith Journal: Pediatrics Date: 2010-03-22 Impact factor: 7.124
Authors: Grace K Dy; Lishan Bekele; Lorelei J Hanson; Alfred Furth; Sumithra Mandrekar; Jeff A Sloan; Alex A Adjei Journal: J Clin Oncol Date: 2004-12-01 Impact factor: 44.544
Authors: M Robyn Andersen; Erin Sweet; Kimberly A Lowe; Leanna J Standish; Charles W Drescher; Barbara A Goff Journal: J Altern Complement Med Date: 2013-02-27 Impact factor: 2.579
Authors: Jin Ge; Jessica Fishman; Neha Vapiwala; Susan Q Li; Krupali Desai; Sharon X Xie; Jun J Mao Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-03 Impact factor: 7.038
Authors: Encouse B Golden; Philip Y Lam; Adel Kardosh; Kevin J Gaffney; Enrique Cadenas; Stan G Louie; Nicos A Petasis; Thomas C Chen; Axel H Schönthal Journal: Blood Date: 2009-02-03 Impact factor: 22.113
Authors: Kent C Nate; Kristen H Griffin; Jon B Christianson; Jeffery A Dusek Journal: Evid Based Complement Alternat Med Date: 2015-11-26 Impact factor: 2.629
Authors: David E Gerber; Thomas Y Sheffield; M Shaalan Beg; Erin L Williams; Valerie L Clark; Yang Xie; M E Blair Holbein; Celette Sugg Skinner; Simon J Craddock Lee Journal: J Natl Compr Canc Netw Date: 2020-10-07 Impact factor: 11.908